Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 141 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
VASO Aktie jetzt für 0€ handeln | |||||
31.03. | VASO Corp - 10-K, Annual Report | 1 | SEC Filings | ||
31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 153 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen | |
13.01. | Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors | 132 | GlobeNewswire (Europe) | PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments... ► Artikel lesen | |
03.01. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
20.12.24 | SRV YHTIOT OYJ: SRV will implement right-of-occupancy housing units for Vaso in Kuloistenniitty, Raisio - the units will have an energy class A rating | 4 | Cision News | ||
16.12.24 | Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025 | 132 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 NEWS RELEASE PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX:... ► Artikel lesen | |
14.11.24 | Vaso Corporation Announces Financial Results for Third Quarter 2024 | 150 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
19.09.24 | Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I | 160 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I ("Achari") to terminate... ► Artikel lesen | |
14.08.24 | Vaso Corporation Announces Financial Results for Second Quarter 2024 | 138 | GlobeNewswire (Europe) | High deferred revenue and backlog setting stage for 2024 revenue and income growth PLAINVIEW, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today reported its operating... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,435 | +0,02 % | Bayer, Vidac Pharma, Evotec - schnappen Sie sich den 866 Milliarden Onkologie Jackpot | Die Onkologie erlebt eine beispiellose Revolution. Mit prognostizierten 866 Mrd. USD Marktvolumen bis 2034 und 11 % Jahreswachstum treiben KI-gestützte Diagnosen, personalisierte Gentherapien und Präzisionsmedizin... ► Artikel lesen | |
ASTRAZENECA | 127,95 | +0,63 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca anlässlich des Onkologie-Jahreskongresses Asco mit einem Kursziel von 14000 Pence auf "Overweight" belassen. James... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,718 | -1,56 % | EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration | - Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 30,650 | +0,46 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
CSPC PHARMA | 0,988 | +1,58 % | Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,430 | +1,42 % | SELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting | - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 19,085 | -1,01 % | JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory | ||
MADRIGAL PHARMACEUTICALS | 243,70 | -0,12 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
CATALYST PHARMACEUTICALS | 22,750 | +0,22 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP... ► Artikel lesen | |
ENZON PHARMACEUTICALS | 0,061 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
OPUS GENETICS | 0,930 | -0,11 % | XFRA R3X1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILOPUS GENETICS DL-... ► Artikel lesen | |
CHUGAI PHARMACEUTICAL | 45,780 | -1,48 % | Rani Therapeutics Announces Research Agreement with Chugai | - Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
VIRACTA THERAPEUTICS | 0,019 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
SAVARA | 2,200 | +2,80 % | Savara wählt Vorstandsmitglieder und genehmigt Vorschläge bei Jahresversammlung |